Education · Tier 1

· Last Reviewed May 12, 2026· PSI Editorial Board· Independent

Do I Need a Doctor for Peptide Therapy?

The honest answer on whether peptides need a prescription, which doctors can prescribe them, what the compounding pharmacy framework requires, and what self-sourcing actually means under US law.

All therapeutic peptides require a physician prescription in the United States.

FDA-approved peptides like Wegovy and Ozempic, compounded peptides from 503A and 503B pharmacies, and any therapeutic injection follow the same legal pathway.

Research-grade peptides sold without a prescription are not a legitimate medical shortcut.

100%

Require a Prescription

Every therapeutic peptide in the US requires a physician prescription, with no exception

503A/B

Compounding Pathway

FDA Compounding Quality Act governs 503A pharmacy and 503B outsourcing facility access

AMA 1.1.5

Off-Label Framework

AMA Code of Medical Ethics 1.1.5 governs off-label prescribing with documented informed consent

FDCA

Federal Drug Law

Federal Food Drug and Cosmetic Act regulates peptide products as drugs, not supplements

Quick Answer

Yes. Every therapeutic peptide in the United States requires a physician prescription. There is no legal over-the-counter peptide therapy pathway.

FDA-approved peptides are prescription drugs. Semaglutide as Wegovy or Ozempic requires a prescription. Tirzepatide as Zepbound or Mounjaro requires a prescription. Teriparatide as Forteo requires a prescription. The same applies to every other FDA-approved peptide.

Compounded peptides require a physician prescription routed through a 503A pharmacy or 503B outsourcing facility under the FDA Compounding Quality Act. Compounded semaglutide and compounded tirzepatide products are prescription-only. Recent FDA scrutiny on compounded GLP-1 receptor agonists confirms the pharmacy quality requirements.

Three prescription pathways are legitimate. Primary care physicians prescribe FDA-approved peptides for common indications. Telehealth physicians prescribe across state lines under valid licensure and state regulation. Specialty practices like endocrinology and weight medicine manage complex cases.

Research-grade peptides sold by online suppliers without a prescription are not a legal shortcut for therapeutic use. The not for human use label places these products outside FDA and state pharmacy board oversight. Self-sourcing carries unknown quality, unknown purity, and real legal exposure.

For specific guidance, see How Physicians Recommend Peptides, Finding a Peptide Doctor, Compounded vs FDA-Approved Peptides, and Telehealth vs In-Person Peptide Prescriptions.

Peptides used for therapy operate under federal prescription drug law. Wegovy and Ozempic for weight management and diabetes are FDA-approved prescription medications. Zepbound and Mounjaro are FDA-approved prescriptions for chronic weight management and type 2 diabetes. Forteo and Evenity are FDA-approved prescriptions for osteoporosis. Compounded peptides like compounded semaglutide require a physician prescription routed through a 503A or 503B compounding pharmacy. The FDA Compounding Quality Act governs that pathway. Off-label use of an FDA-approved peptide is legal under AMA Code of Medical Ethics 1.1.5 with documented informed consent. Telehealth peptide consultations are valid prescription pathways when a licensed physician establishes the patient relationship per state law. Research-grade peptides labeled not for human use are sold outside the FDA and state pharmacy board framework. Patients self-sourcing those products operate outside validated clinical practice with unknown quality and unknown safety. PSI tracks the full regulatory and prescription framework for evidence-graded peptide therapy.

WHICH PRESCRIPTION SCENARIO?

At a Glance: Do I Need a Doctor for Peptides

Patient Scenario	Subtitle	Animal Evidence	Human Evidence	Prescription Pathway
Adult seeking FDA-approved weight management peptide	Primary care or weight medicine prescription	—	Strong	Wegovy or Zepbound per FDA labeling with primary care or obesity medicine specialty
Adult seeking FDA-approved type 2 diabetes peptide	Primary care or endocrinology prescription	—	Strong	Ozempic or Mounjaro per ADA Standards of Care with primary care or endocrinology
Adult seeking FDA-approved osteoporosis peptide	Endocrinology or rheumatology prescription	—	Strong	Forteo, Tymlos, or Evenity for high fracture risk per AACE/ACE 2020 framework
Adult seeking compounded peptide	Physician routing through 503A or 503B pharmacy	—	Moderate	Compounding Quality Act framework with documented pharmacy due diligence
Adult seeking off-label use of FDA-approved peptide	Prescription with documented informed consent	—	Moderate	Legal under AMA Code of Medical Ethics 1.1.5 with documented risk-benefit assessment
Adult considering telehealth peptide consult	Telehealth prescription within state law	—	Strong	Licensed physician with established relationship per state telehealth regulation
Adult considering research-grade peptide from online supplier	Not a legitimate physician-free pathway	—	Limited	Outside FDA and state pharmacy board framework; refer to clinical trial or alternative
Adult self-sourcing without prescription	Outside validated clinical practice entirely	—	Limited	Unknown quality, unknown purity, unknown sterility; real legal exposure

Five Things You Need to Know About Peptide Prescriptions

This page covers whether peptide therapy requires a doctor in the United States. The answer is yes for every therapeutic peptide. The framework spans five sections. Section one establishes that all therapeutic peptides are prescription-only under federal drug law. Section two maps the three legitimate prescription pathways including primary care, telehealth, and specialty practice. Section three explains the compounded peptide pathway through 503A and 503B pharmacies per the FDA Compounding Quality Act. Section four addresses research-grade peptides and why those are not a physician-free shortcut. Section five covers what self-sourcing actually means under federal and state law including quality, safety, and legal exposure.

All Therapeutic Peptides Require a Prescription in the United States

There is no legal over-the-counter peptide therapy pathway. Every therapeutic peptide is a prescription drug under federal law.

Federal drug law treats therapeutic peptides as prescription medications under the Federal Food Drug and Cosmetic Act. FDA-approved peptides including Semaglutide as Wegovy and Ozempic, Tirzepatide as Zepbound and Mounjaro, Liraglutide as Saxenda and Victoza, Teriparatide as Forteo, Abaloparatide as Tymlos, Romosozumab as Evenity, Sermorelin, and Tesamorelin as Egrifta are all prescription medications. Compounded peptides require a physician prescription routed through a 503A pharmacy for individual patient prescriptions or a 503B outsourcing facility under the FDA Compounding Quality Act. The prescription requirement is not a clinical formality. It is the legal gate. Distinguishing therapeutic peptides from collagen supplements or creatine is essential. Dietary supplements sold under DSHEA do not require a prescription, but therapeutic peptide injections do. Self-sourcing therapeutic peptides without a prescription is outside the FDA framework. Patients should consult your physician for any therapeutic peptide consideration.

Three Legitimate Prescription Pathways: Primary Care, Telehealth, Specialty

Three prescription pathways are legitimate. Primary care handles routine FDA-approved peptide indications, telehealth covers established physician-patient relationships across state lines, and specialty practices manage complex cases.

Primary care physicians can and do prescribe FDA-approved peptides for common indications. Primary care prescribes Wegovy and Saxenda for chronic weight management, Ozempic and Victoza for type 2 diabetes, and other FDA-approved peptides within established frameworks. Telehealth peptide prescriptions are valid when a licensed physician establishes the patient relationship per state regulation. State medical boards govern telehealth scope across state lines. Some states require the physician to hold a license in the patient state. Other states permit interstate prescribing under compact arrangements. Specialty practices manage complex cases. Endocrinology handles complex hormone and metabolic peptide therapy. Weight medicine specialists manage comprehensive obesity care. Rheumatology handles osteoporosis with rheumatologic conditions. Urology and men's health handle sexual health peptide considerations. For complex multi-system patients, specialty coordination across primary care and specialty practice is the standard framework. Discuss with your physician which pathway fits your clinical context.

Compounded Peptides Route Through Licensed 503A or 503B Pharmacies

Compounded peptides require a physician prescription routed through a licensed compounding pharmacy under the FDA Compounding Quality Act. The pharmacy framework is the legal gate.

The FDA Compounding Quality Act defines two compounding pharmacy categories. 503A pharmacies compound for individual patient prescriptions under state pharmacy board oversight. The pharmacy receives the prescription from a licensed physician for a specific patient. 503B outsourcing facilities compound in bulk under FDA registration and inspection. Neither category receives FDA pre-market approval for the compounded product. The physician routes the prescription. Patients cannot order compounded peptides directly from a pharmacy without a prescription. Physician due diligence on compounded peptide products includes verifying state license, accreditation status, third-party purity and potency testing, sterility certification, USP standards compliance, and adverse event reporting practices. Recent FDA scrutiny on compounded GLP-1 receptor agonists including compounded semaglutide and compounded tirzepatide has highlighted the importance of careful pharmacy sourcing. Patients exploring compounded peptide options should consult your physician to verify pharmacy quality assurance before any compounded prescription. Specialty coordination strengthens compounded peptide decisions for complex cases.

Research-Grade Peptides Are Not a Physician-Free Shortcut

Research-grade peptides sold by online suppliers without a prescription are outside the FDA and state pharmacy board framework. The not for human use label is legally meaningful.

Research suppliers sell peptides labeled research only or not for human use. These products are sold for laboratory research purposes outside the FDA and state pharmacy board framework. The labels are not marketing language. They are legal language separating research chemicals from therapeutic drugs. Research-grade peptides do not undergo FDA pre-market approval. Quality, purity, and sterility are not guaranteed. Adverse event reporting is not required of the supplier. Patient self-sourcing of research-grade peptides for therapeutic use operates outside validated clinical practice. Physicians do not generally recommend research-grade peptide products. The appropriate pathway for compounds with preliminary evidence is clinical trial enrollment or referral to validated alternatives. Anyone framing research-grade peptides as a legal alternative to physician-prescribed therapy is making a claim that does not hold under FDA enforcement framework. The not for human use label is the supplier's legal disclaimer. Using the product for human therapy crosses that disclaimer. Patients considering peptide therapy should consult your physician for legitimate options.

Self-Sourcing Operates Outside FDA Framework With Real Risk

Self-sourcing therapeutic peptides without a prescription operates outside validated clinical practice. Quality, purity, sterility, and legal exposure are real concerns.

Self-sourcing therapeutic peptides creates multiple categories of risk. Quality risk includes unknown purity, unknown peptide identity, unknown manufacturing standards, and unknown adulterants. Sterility risk includes contamination of injectable products with bacteria, endotoxins, or other contaminants. Safety risk includes unknown adverse event profile, unknown drug interaction profile, and absence of monitoring or follow-up. Regulatory risk includes potential customs seizure of imported products, potential criminal exposure depending on the substance and quantity, and potential civil exposure if harm occurs. Insurance generally does not cover self-sourced products. Medical malpractice frameworks do not apply outside the physician-patient relationship. Patient self-sourcing typically excludes the ability to engage a physician for monitoring without disclosing the self-sourcing pathway, which itself creates a clinical relationship complication. Patients considering peptide therapy should pursue physician-supervised pathways through primary care, telehealth, or specialty. Consult your physician to evaluate FDA-approved options first. For compounded peptide consideration, ensure your physician verifies pharmacy quality assurance. Specialty coordination strengthens complex decisions across primary care and specialty practice.

Prescription status: FDA-approved vs compounded vs research-grade vs supplement

The four regulatory categories and what prescription requirement each carries

FDA-approved peptides are prescription drugs under the Federal Food Drug and Cosmetic Act. The FDA reviews safety, efficacy, manufacturing quality, and labeling before approval. Wegovy and Ozempic carry FDA approval for chronic weight management and type 2 diabetes with cardiovascular benefit. Zepbound and Mounjaro carry FDA approval for chronic weight management and type 2 diabetes. Saxenda and Victoza carry FDA approval for chronic weight management and type 2 diabetes. Forteo carries FDA approval for postmenopausal, male, and glucocorticoid-induced osteoporosis. Tymlos carries FDA approval for postmenopausal and male osteoporosis. Evenity carries FDA approval for postmenopausal osteoporosis at high fracture risk. Sermorelin and Tesamorelin as Egrifta also carry FDA approval. Every one is prescription-only by federal law.

Compounded peptides are prescription drugs that route through a licensed compounding pharmacy. The FDA Compounding Quality Act defines 503A pharmacies (compounding for individual patient prescriptions under state pharmacy board oversight) and 503B outsourcing facilities (bulk compounding under FDA registration and inspection). Neither category receives FDA pre-market approval for the compounded product itself. The prescription requirement is identical to FDA-approved peptides. The pharmacy oversight framework differs. Compounded semaglutide, compounded tirzepatide, and other compounded peptide preparations all require a physician prescription.

Research-grade peptides labeled not for human use are sold outside the FDA and state pharmacy board framework. These products are sold for laboratory research, not therapeutic use. The labels are legal language separating research chemicals from therapeutic drugs. Research suppliers do not undergo FDA pre-market approval. Quality, purity, sterility, and adverse event reporting are not guaranteed or required. Patient self-sourcing of research-grade peptides for therapeutic use crosses the supplier disclaimer and operates outside validated clinical practice.

Dietary supplements like collagen peptides, creatine, and amino acid supplements operate under the Dietary Supplement Health and Education Act (DSHEA). DSHEA supplements do not require a prescription but also cannot make therapeutic claims, treat disease, or be marketed as drug equivalents. The DSHEA supplement category is genuinely over-the-counter. Therapeutic peptides like GLP-1 receptor agonists, growth hormone secretagogues, and tissue repair peptides are not DSHEA supplements. The categorical distinction is the legal gate between OTC and prescription-only.

Prescription pathway: primary care vs telehealth vs specialty practice

The three legitimate routes to a peptide prescription in the United States

Primary care physicians prescribe FDA-approved peptides for common indications. Primary care prescribes Wegovy and Saxenda for chronic weight management when patients meet FDA-approved criteria. Primary care prescribes Ozempic and Victoza for type 2 diabetes per ADA Standards of Care. Primary care manages baseline evaluation, comprehensive history and physical, indicated labs, and ongoing monitoring. The primary care pathway is the most common route to FDA-approved peptide therapy. Complex multi-system cases, off-label considerations, or specific specialty disorder presentations typically trigger specialty referral.

Telehealth peptide consultations are valid prescription pathways when a licensed physician establishes the physician-patient relationship per state regulation. State medical boards govern telehealth scope across state lines. Some states require the physician to hold a license in the patient state of residence. Other states permit interstate prescribing under compact arrangements like the Interstate Medical Licensure Compact. Telehealth physicians conduct comprehensive evaluation including history, indicated labs, and follow-up. Wegovy and Ozempic prescribing via telehealth is common for chronic weight management. Patients should verify the telehealth physician holds appropriate state licensure and the consultation establishes a valid physician-patient relationship.

Specialty practice manages complex multi-system patients and off-label considerations. Endocrinology specialty manages complex hormone and metabolic peptide therapy. Weight medicine specialists (obesity medicine specialty board certified) manage comprehensive obesity care including FDA-approved Wegovy, Zepbound, and Saxenda within established frameworks. Rheumatology specialty manages osteoporosis with rheumatologic conditions or glucocorticoid-induced disease. Cardiology manages cardiovascular indications including SELECT-supported Wegovy use. Urology and men's health manage sexual health peptide considerations. Specialty coordination strengthens complex decisions through documented multi-specialty review per AMA Code of Medical Ethics.

Any of these three pathways produces a valid prescription. The patient choice depends on clinical complexity, geography, insurance coverage, and physician availability. Primary care is the most common and most insurance-friendly. Telehealth expands geographic access. Specialty practice provides depth of expertise. Patients should consult your physician about which pathway fits your clinical context and FDA-approved indication match.

Compounding pharmacy framework: 503A vs 503B vs research suppliers

How the FDA Compounding Quality Act governs compounded peptide access

The FDA Compounding Quality Act of 2013 amended the Federal Food Drug and Cosmetic Act to define two compounding pharmacy categories. 503A pharmacies compound for individual patient prescriptions under state pharmacy board oversight. The pharmacy receives the prescription from a licensed physician for a specific patient. State boards regulate licensing, inspection, and adverse event reporting. The FDA does not pre-approve 503A compounded products. Physician due diligence on 503A compounded peptide prescriptions includes verifying state license, accreditation status (PCAB or equivalent), third-party purity and potency testing, sterility certification, and USP Chapter 797 and 800 standards compliance.

503B outsourcing facilities compound in bulk under FDA registration and inspection. The FDA registers and inspects 503B facilities directly. 503B compounded products may be used by physicians for office stock or specific patient prescriptions. The 503B framework was created after the 2012 New England Compounding Center meningitis outbreak to provide FDA oversight for bulk-compounded sterile products. Physician due diligence on 503B compounded peptide products includes verifying FDA registration, inspection history, and adverse event reporting compliance.

Recent FDA scrutiny on compounded GLP-1 receptor agonists has highlighted compounding pharmacy quality variability. The FDA issued guidance addressing compounded semaglutide and compounded tirzepatide products, including warnings about salt-form variants of the FDA-approved molecules. The agency has pursued enforcement against facilities producing substandard compounded GLP-1 products. Patients pursuing compounded GLP-1 therapy should work with physicians who verify pharmacy quality assurance and FDA registration status. The compounded pathway is legitimate when the pharmacy meets the regulatory standard. The pathway becomes problematic when the pharmacy operates outside the framework.

Research suppliers selling research-grade or not-for-human-use peptides operate outside the FDA Compounding Quality Act framework entirely. These suppliers are not 503A pharmacies. These suppliers are not 503B outsourcing facilities. The product labels are not therapeutic drug labels. Physicians do not generally prescribe through research suppliers. Patient self-sourcing from research suppliers does not create a compounding pathway and does not produce a prescription. The framework is structurally different. Patients considering peptide therapy should pursue the FDA-approved or compounded pharmacy pathways through a physician, not the research supplier route.

What self-sourcing actually means: legal status, FDA enforcement, safety risk

The legal, regulatory, and clinical implications of bypassing the prescription framework

Self-sourcing therapeutic peptides without a prescription operates outside federal drug law and state pharmacy board oversight. The Federal Food Drug and Cosmetic Act categorizes therapeutic peptide injectables as prescription drugs. Selling, distributing, or importing prescription drugs without authorization is a federal violation. Personal importation of small quantities may fall under FDA Personal Importation Policy guidance, but the policy is discretionary and does not legalize therapeutic use of products without a prescription. The not for human use label on research-grade products is the supplier's legal disclaimer separating research chemical commerce from therapeutic drug sales.

Quality, purity, and sterility of self-sourced products are not guaranteed. Independent testing of research-grade peptide products has identified variable potency, identity mismatches, bacterial contamination, endotoxin contamination, and adulterants. Sterility is particularly critical for injectable products. Compounding pharmacy USP Chapter 797 and 800 standards exist because injectable contamination causes documented patient harm. Research suppliers do not operate under these standards. Self-sourcing injectable products carries real infection risk including bacterial sepsis and endotoxin reactions.

Safety risk extends beyond product quality. Self-sourcing excludes baseline evaluation including history, contraindication review, indicated labs, and drug interaction screening. Self-sourcing excludes monitoring including response assessment, side effect recognition, and adjustment protocols. Self-sourcing excludes the ability to engage a physician for adverse event management without disclosing the self-sourcing pathway, which itself creates a clinical relationship complication. Patients who develop adverse events from self-sourced products may face stigma or reluctance when seeking medical care, which compromises care timing.

The PSI position on self-sourcing is unambiguous. The pathway is not validated clinical practice. The pathway carries unknown quality, unknown safety, and real legal exposure. Patients considering peptide therapy should pursue physician-supervised pathways through primary care, telehealth, or specialty. Consult your physician for FDA-approved evaluation first. For compounded peptide consideration, work with physicians who verify pharmacy quality assurance and operate within the FDA Compounding Quality Act framework. Specialty coordination strengthens complex decisions. PSI maintains a vetted directory of practitioners with peptide experience who operate within validated clinical practice frameworks.

Research Suggests

Direction

Federal drug law and state pharmacy board oversight together establish that every therapeutic peptide in the United States requires a physician prescription.

The Federal Food Drug and Cosmetic Act categorizes therapeutic peptide injectables as prescription drugs. The FDA Compounding Quality Act extends this framework to compounded preparations through 503A pharmacies and 503B outsourcing facilities. AMA Code of Medical Ethics 1.1.5 governs off-label prescribing of FDA-approved peptides with documented informed consent. AMA Code 2.1.1 establishes the informed consent framework. State pharmacy boards govern compounding pharmacy licensure, inspection, and adverse event reporting. Telehealth prescribing operates under state medical board scope including interstate compact arrangements. The framework is consistent across all three legitimate pathways: primary care, telehealth, and specialty practice. Self-sourcing operates outside this framework. There is no statutory or regulatory pathway for over-the-counter therapeutic peptide access in the United States.

Strongest evidence

FDA-approved peptide prescribing through primary care or specialty has the strongest legal, evidence, and regulatory foundation.

FDA-approved peptides have Phase 3 trial evidence demonstrating safety and efficacy for specific indications. The FDA prescribing information includes indication, contraindications, warnings, dosing, monitoring requirements, and adverse event profiles. Wegovy SELECT trial demonstrated 20 percent MACE reduction. Ozempic SUSTAIN-6 demonstrated cardiovascular benefit in type 2 diabetes. Zepbound SURMOUNT demonstrated approximately 21 percent weight reduction. Forteo Phase 3 demonstrated approximately 65 percent vertebral fracture reduction. The prescription pathway through primary care or specialty practice provides documentation, monitoring, drug interaction screening, and adverse event response infrastructure. Insurance coverage is generally available for FDA-approved indications with prior authorization. The FDA-approved pathway is the evidence-graded and legally protected default for patients seeking therapeutic peptide therapy.

Limitations

Off-label and compounded pathways apply selectively under additional documentation and physician due diligence requirements.

Off-label use of FDA-approved peptides is legal but requires documented informed consent per AMA Code of Medical Ethics 1.1.5. The evidence base for off-label indications varies. Compounded peptides do not receive FDA pre-market approval for the compounded product. Quality assurance depends on pharmacy practices including third-party testing, USP Chapter 797 and 800 compliance, and adverse event reporting. Recent FDA scrutiny on compounded GLP-1 receptor agonists confirms compounding pharmacy quality variability across the marketplace. Telehealth prescribing scope varies by state. Some states require physician licensure in the patient state. Other states permit interstate prescribing under compact arrangements. Patients should verify telehealth physician credentials and state scope.

Assessment

FDA-approved prescription pathways dominate evidence-graded peptide practice. Compounded pathways apply under physician due diligence. Self-sourcing is structurally outside validated clinical practice.

PSI's reading: every therapeutic peptide in the United States requires a physician prescription. The three legitimate prescription pathways are primary care, telehealth, and specialty practice. FDA-approved peptides through any of these pathways carry the strongest evidence and regulatory foundation. Off-label use of FDA-approved peptides is legal under AMA Code with documented informed consent. Compounded peptides operate through 503A pharmacies and 503B outsourcing facilities under the FDA Compounding Quality Act. Physician due diligence on compounding pharmacy quality assurance is essential. Research-grade peptides sold without prescription are outside the FDA framework and outside validated clinical practice. Patient self-sourcing carries unknown quality, unknown sterility, and real legal exposure. Anyone framing research-grade peptide self-sourcing as a legitimate alternative to physician-prescribed therapy is making a claim that does not hold under federal and state law. Consult your physician for evidence-graded options. PSI maintains a vetted directory of practitioners for patients pursuing evidence-graded peptide therapy.

How to Approach Your Decision

Limitations and Caveats

All therapeutic peptides require a prescription in the United States. Federal drug law treats peptide injectables as prescription drugs under the Federal Food Drug and Cosmetic Act. No over-the-counter pathway exists.
Compounded peptides require physician routing through 503A or 503B pharmacies. The FDA Compounding Quality Act governs the framework. Direct patient ordering from compounding pharmacies is not permitted.
Off-label prescribing is legal but requires documented informed consent. AMA Code of Medical Ethics 1.1.5 establishes the framework. Documentation requirements are not optional.
Telehealth scope varies by state. Some states require physician licensure in the patient state. Other states permit interstate prescribing under compact arrangements. Patients should verify physician credentials.
Research-grade peptides are sold outside the FDA framework. The not for human use label is legal language. Self-sourcing for therapeutic use crosses the supplier disclaimer.
Self-sourcing carries unknown quality, unknown sterility, and real legal exposure. Independent testing of research-grade products has identified variable potency, contamination, and adulterants.
Insurance coverage varies by indication and product. FDA-approved indications generally have better coverage than off-label use. Compounded products are typically not covered. Self-sourced products are never covered.
Specialty coordination strengthens complex decisions. Multi-system patients benefit from documented multi-specialty review per AMA Code of Medical Ethics framework.

What's Marketed vs What's Studied

7 common claims, corrected.

“Peptides are supplements and can be bought over the counter without a prescription.”

Therapeutic peptide injectables like Semaglutide, Tirzepatide, Teriparatide, and Romosozumab are prescription drugs under the Federal Food Drug and Cosmetic Act. DSHEA dietary supplements like collagen peptides and creatine are categorically separate from therapeutic peptides. No over-the-counter pathway exists for therapeutic peptide injectables in the United States.

“Research-grade peptides labeled not for human use are legally available so they are a valid alternative to a prescription.”

The not for human use label is a legal disclaimer separating research chemical commerce from therapeutic drug sales under FDA enforcement framework. Using the product for human therapy crosses that disclaimer. Patient self-sourcing for therapeutic use operates outside the FDA and state pharmacy board oversight regardless of the legality of laboratory research chemical sales.

“Compounded peptides are unregulated because they do not have FDA approval.”

Compounded peptides operate under the FDA Compounding Quality Act framework. 503A pharmacies compound for individual patient prescriptions under state pharmacy board oversight. 503B outsourcing facilities compound in bulk under FDA registration and inspection. Both require a physician prescription. Quality assurance depends on pharmacy practices including third-party testing and USP Chapter 797 and 800 compliance.

“Telehealth peptide prescriptions are a legal gray area or not valid.”

Telehealth peptide prescriptions are valid when a licensed physician establishes the physician-patient relationship per state regulation. State medical boards govern interstate scope. The Interstate Medical Licensure Compact permits cross-state prescribing in participating states. Patients should verify physician credentials and state-specific scope before any telehealth consultation.

“You need to see an endocrinologist or specialist to get any peptide prescription.”

Primary care physicians prescribe FDA-approved peptides for common indications. Primary care prescribes Wegovy and Saxenda for chronic weight management. Primary care prescribes Ozempic and Victoza for type 2 diabetes per ADA Standards of Care. Specialty referral is appropriate for complex multi-system patients, off-label considerations, or specialty-specific disorders rather than the default pathway.

“Off-label use of FDA-approved peptides is illegal or non-standard practice.”

Off-label prescribing of FDA-approved peptides is legal under AMA Code of Medical Ethics 1.1.5 with documented informed consent. AMA Code 2.1.1 establishes the informed consent framework. Off-label use is standard medical practice across many specialties when supported by evidence and documented risk-benefit assessment.

“Buying peptides online is no different from buying creatine or collagen supplements.”

Creatine, collagen peptides, and amino acid supplements are DSHEA dietary supplements with categorically different regulation than prescription drugs. Therapeutic peptide injectables like Semaglutide, Tirzepatide, Teriparatide, and Romosozumab are prescription drugs under federal law. Online availability of research-grade products does not change the regulatory category or legalize therapeutic use.

Common Questions

Do I need a prescription for any peptide therapy in the United States?

Yes. Every therapeutic peptide in the United States requires a physician prescription. This applies to FDA-approved peptides like Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, Forteo, Tymlos, Evenity, Sermorelin, and Tesamorelin as well as compounded peptides routed through 503A or 503B pharmacies. There is no legal over-the-counter therapeutic peptide pathway.

Are peptides considered supplements or drugs under federal law?

Therapeutic peptide injectables are prescription drugs under the Federal Food Drug and Cosmetic Act. Dietary supplements like collagen peptides, creatine, and amino acid supplements operate under the Dietary Supplement Health and Education Act (DSHEA). The categorical distinction is the legal gate between OTC supplements and prescription-only therapeutic peptides.

Are research-grade peptides legal to buy online?

Research-grade peptides labeled not for human use are sold for laboratory research purposes outside the FDA and state pharmacy board framework. Patient self-sourcing for therapeutic use operates outside validated clinical practice. The not for human use label is a legal disclaimer. Using the product for human therapy crosses that disclaimer and operates outside the FDA framework.

What is the difference between FDA-approved and compounded peptides?

FDA-approved peptides have undergone FDA pre-market review including Phase 3 trial evidence demonstrating safety and efficacy for specific indications. Compounded peptides do not receive FDA pre-market approval but route through 503A pharmacies or 503B outsourcing facilities under the FDA Compounding Quality Act. Both require a physician prescription. The regulatory frameworks differ but both pathways are prescription-only.

Can my primary care doctor prescribe Wegovy or Ozempic?

Yes. Primary care physicians can and do prescribe FDA-approved peptides for common indications. Primary care prescribes Wegovy and Saxenda for chronic weight management when patients meet FDA-approved criteria. Primary care prescribes Ozempic and Victoza for type 2 diabetes per ADA Standards of Care. Discuss with your primary care physician whether the FDA-approved indication matches your clinical context.

Do I need to see an endocrinologist for peptide therapy?

Not necessarily. Primary care manages FDA-approved peptide prescribing for common weight management and type 2 diabetes indications. Endocrinology specialty referral is appropriate for complex hormone and metabolic peptide therapy, complex multi-system patients, or specialty-specific disorder presentations. Consult your physician about whether specialty coordination strengthens your specific clinical context.

Is telehealth a valid pathway for peptide prescriptions?

Yes, when the telehealth physician holds appropriate state licensure and the consultation establishes a valid physician-patient relationship per state regulation. State medical boards govern telehealth scope across state lines. Some states require physician licensure in the patient state. Other states permit interstate prescribing under the Interstate Medical Licensure Compact. Patients should verify telehealth physician credentials.

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

The FDA Compounding Quality Act defines two compounding pharmacy categories. 503A pharmacies compound for individual patient prescriptions under state pharmacy board oversight. 503B outsourcing facilities compound in bulk under FDA registration and inspection. 503A is patient-specific compounding. 503B is bulk compounding for office stock or specific patient prescriptions. Both require a physician prescription.

Is off-label peptide prescribing legal?

Yes. Off-label use of FDA-approved peptides is legal under AMA Code of Medical Ethics 1.1.5 with documented informed consent. AMA Code 2.1.1 establishes the informed consent framework. Documented risk-benefit assessment is required. Off-label prescribing is standard medical practice across many specialties when supported by evidence and documented per AMA framework.

What are the legal risks of self-sourcing therapeutic peptides?

Self-sourcing therapeutic peptides operates outside federal drug law and state pharmacy board oversight. Selling, distributing, or importing prescription drugs without authorization is a federal violation. Personal importation may fall under discretionary FDA Personal Importation Policy guidance, but the policy does not legalize therapeutic use. Customs seizure, civil exposure if harm occurs, and inability to engage physicians for monitoring without complication are real concerns.

What is the difference between collagen peptide supplements and therapeutic peptides like semaglutide?

Collagen peptides are DSHEA dietary supplements sold over the counter. They are ingested orally and metabolized through normal digestion. Therapeutic peptides like Semaglutide and Tirzepatide are prescription injectable drugs that act on specific receptor targets like GLP-1. The molecular structure, mechanism, regulatory category, and prescription requirement differ fundamentally.

Why has the FDA scrutinized compounded GLP-1 peptides?

The FDA has issued guidance on compounded semaglutide and compounded tirzepatide products including warnings about salt-form variants of the FDA-approved molecules. The agency has pursued enforcement against facilities producing substandard products. Patients pursuing compounded GLP-1 therapy should work with physicians who verify pharmacy quality assurance including third-party testing and USP standards compliance.

Does insurance cover compounded semaglutide?

Compounded peptide products are typically not covered by insurance. FDA-approved Wegovy, Ozempic, and Saxenda may be covered for FDA-approved indications with prior authorization. Coverage varies by plan, indication, and prior authorization requirements. Patients should verify coverage with their insurance plan and discuss with your physician before pursuing compounded peptide pathways.

What documentation is required for off-label peptide prescribing?

AMA Code of Medical Ethics 1.1.5 requires documented informed consent including risk-benefit assessment, alternative options reviewed, and patient understanding. AMA Code 2.1.1 establishes the informed consent framework. Documentation typically includes clinical reasoning supporting the off-label use, evidence base referenced, risk and benefit discussion, and patient acknowledgment. Specialty coordination strengthens complex off-label decisions.

Are therapeutic peptides controlled substances?

Most therapeutic peptides including GLP-1 receptor agonists (Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza) and osteoporosis peptides (Forteo, Tymlos, Evenity) are not DEA controlled substances. They are prescription drugs under the Federal Food Drug and Cosmetic Act but not scheduled under the Controlled Substances Act. The prescription requirement comes from FDA approval status rather than DEA scheduling.

What does AMA Code of Medical Ethics require for off-label peptide use?

AMA Code of Medical Ethics 1.1.5 requires that physicians prescribing off-label have a reasonable basis for use, document the clinical reasoning, obtain informed consent including risk-benefit assessment, and provide appropriate monitoring. AMA Code 2.1.1 establishes the informed consent framework as central to ethical prescribing practice.

What are red flags when choosing a telehealth peptide clinic?

Red flags include absence of physician licensure verification, missing state-specific scope documentation, refusal to address baseline evaluation and indicated labs, vendor-funded prescribing relationships, lack of adverse event response protocols, and absence of documented informed consent for off-label use. Patients should verify the telehealth physician holds appropriate state licensure and the consultation establishes a valid physician-patient relationship.

What should I do if a clinic offers peptide therapy without a physician evaluation?

A clinic offering therapeutic peptide therapy without a physician evaluation is operating outside the standard prescription framework. Therapeutic peptide therapy requires a physician-patient relationship per federal and state law. Patients should decline therapy from any setting that bypasses physician evaluation, even when products are framed as nutritional or supplemental. Discuss with your physician about validated prescription pathways.

Sourcing Checklist

Verify the physician is licensed in your state of residence with active unrestricted status.
State medical boards maintain online license verification portals. Confirm the physician's primary state license is active and unrestricted. For telehealth across state lines, verify either direct licensure in your state or participation in the Interstate Medical Licensure Compact.
Confirm a valid physician-patient relationship is established per state regulation.
State law defines what constitutes a valid physician-patient relationship including required evaluation, history-taking, and documentation. The consultation should include comprehensive history, indicated baseline labs, and contraindication review. Patients should consult your physician about expected baseline evaluation scope.
For compounded peptide consideration, verify the pharmacy is 503A or 503B with appropriate accreditation.
503A pharmacies operate under state pharmacy board licensure. 503B outsourcing facilities operate under FDA registration and inspection. PCAB accreditation, third-party purity and potency testing, USP Chapter 797 and 800 compliance, and adverse event reporting practices are key quality indicators. Discuss with your physician about pharmacy due diligence.
Verify FDA prescribing information alignment for any FDA-approved peptide under consideration.
FDA prescribing information for Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, Forteo, Tymlos, Evenity, Sermorelin, and Tesamorelin specifies indication, contraindications, dosing, monitoring, and warnings. Physician prescribing should align with FDA labeling for on-label use or document risk-benefit assessment for off-label use per AMA Code 1.1.5.
Confirm informed consent documentation for off-label peptide use.
AMA Code of Medical Ethics 1.1.5 requires documented risk-benefit assessment, alternatives reviewed, and patient understanding. AMA Code 2.1.1 establishes informed consent framework. Patients can request copies of consent documentation for off-label prescribing decisions.
Verify monitoring and adverse event response protocols are in place.
Therapeutic peptide therapy includes ongoing monitoring including indicated labs, response assessment, side effect recognition, and adjustment protocols. Discuss with your physician about expected monitoring frequency, follow-up cadence, and adverse event communication pathway.
Decline any clinic or source operating outside the physician prescription framework.
Clinics offering therapeutic peptide therapy without physician evaluation, sources selling not-for-human-use products framed for therapeutic use, and pathways bypassing pharmacy oversight all operate outside validated clinical practice. Patients should decline therapy from any setting bypassing physician evaluation regardless of marketing framing.

Regulatory Context

Federal drug law and state pharmacy board oversight evolve continuously. FDA scrutiny on compounded GLP-1 peptides has expanded since 2024, with guidance addressing salt-form variants of FDA-approved molecules and enforcement against substandard compounding facilities. State telehealth scope continues to evolve, with the Interstate Medical Licensure Compact expanding cross-state prescribing in participating states. AMA Code of Medical Ethics 1.1.5 and 2.1.1 frameworks for off-label prescribing and informed consent remain foundational. FDA-approved peptide indications continue to expand including Wegovy SELECT cardiovascular benefit expansion in 2023. PSI tracks regulatory changes and updates page content per the Editorial Standards review cadence. Discuss with your physician for the most current regulatory and clinical guidance.

Comparison

Pathway	Prescription required?	Regulatory framework	Typical setting	Insurance coverage
FDA-approved (on-label)	Yes - physician prescription	FDA pre-market approval + prescribing information	Primary care, telehealth, specialty	Generally available with prior authorization
FDA-approved (off-label)	Yes - with documented informed consent	AMA Code 1.1.5 + 2.1.1	Specialty more common, primary care possible	Variable, often case-by-case
Compounded peptide	Yes - routed through 503A or 503B pharmacy	FDA Compounding Quality Act + state pharmacy boards	Specialty practice, telehealth, some primary care	Typically not covered by insurance
Research-grade self-source	No, but outside FDA framework	Not-for-human-use disclaimer + FDA enforcement	Outside validated clinical practice	Never covered + real legal exposure
DSHEA supplement (collagen, creatine)	No, over-the-counter	Dietary Supplement Health and Education Act	Retail, consumer purchase	Out of pocket consumer purchase

Who This Applies To

· Adult considering any therapeutic peptide and verifying prescription requirements under US federal drug law.
· Adult with chronic weight management need evaluating FDA-approved Wegovy, Zepbound, or Saxenda with primary care or weight medicine.
· Adult with type 2 diabetes evaluating FDA-approved Ozempic, Mounjaro, or Victoza with endocrinology or primary care.
· Adult with high fracture risk osteoporosis evaluating FDA-approved Forteo, Tymlos, or Evenity with endocrinology or rheumatology.
· Adult evaluating compounded peptide pathway through 503A or 503B pharmacies under physician routing per FDA Compounding Quality Act.
· Adult considering off-label use of FDA-approved peptide with documented informed consent per AMA Code of Medical Ethics 1.1.5.
· Adult evaluating telehealth peptide consultation across state lines with appropriate state licensure verification.
· Patient offered peptide therapy without physician evaluation and verifying legitimacy of the prescription pathway.
· Patient evaluating research-grade peptide product offers against FDA framework and considering FDA-approved alternatives.
· Patient distinguishing therapeutic peptide drugs from DSHEA dietary supplements like collagen peptides and creatine.

Verdict

All therapeutic peptides in the United States require a physician prescription. FDA-approved peptides like Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Victoza, Forteo, Tymlos, and Evenity are prescription drugs. Compounded peptides require a physician prescription routed through 503A or 503B pharmacies. The FDA Compounding Quality Act governs the framework. Three legitimate prescription pathways exist for patients. Primary care physicians prescribe FDA-approved peptides for common indications. Telehealth peptide prescriptions are valid with appropriate state licensure. Specialty practices including endocrinology and weight medicine manage complex cases. Off-label use of FDA-approved peptides is legal with documented informed consent. AMA Code of Medical Ethics 1.1.5 governs the framework. Research-grade peptides sold online are not a legitimate physician-free shortcut. The not-for-human-use label is a legal disclaimer with FDA enforcement meaning. Self-sourcing therapeutic peptides operates outside validated clinical practice. Quality, sterility, and legal exposure are real concerns with self-sourcing. Patients should consult your physician for evidence-graded prescription options. PSI maintains a vetted directory of practitioners with peptide experience.

In Plain Terms

All therapeutic peptides in the United States require a physician prescription. There is no over-the-counter pathway for therapeutic peptide injectables. FDA-approved peptides like Wegovy and Ozempic are prescription drugs. Compounded peptides also require a physician prescription. Three legitimate pathways exist: primary care, telehealth, and specialty practice. Primary care prescribes FDA-approved peptides for common indications. Telehealth is valid when the physician has appropriate state licensure. Specialty practices manage complex multi-system cases. Research-grade peptides sold online are not a legal physician-free shortcut. The not-for-human-use label is a legal disclaimer. Self-sourcing operates outside the FDA framework with real risk. Discuss with your physician about legitimate prescription pathways.

Peptides are short chains of amino acids that act as signaling messengers in the body. Some peptides are FDA-approved prescription drugs you can get from your doctor with a prescription. Wegovy and Ozempic are FDA-approved for weight loss and type 2 diabetes. Forteo, Tymlos, and Evenity are FDA-approved for osteoporosis at high fracture risk. Other peptides are compounded by special pharmacies and require a physician to write the prescription. Some peptides sold online by research suppliers are not approved for human use. Those are sold for laboratory research, not for therapy. Buying them for therapy operates outside FDA oversight with real risk. The collagen peptides and creatine you can buy at the store are different. Those are dietary supplements, not therapeutic peptide injectables.

For any therapeutic peptide consideration, the physician prescription framework is the legal gate. Discuss with your physician about FDA-approved options first, then evaluate compounded pathways through 503A or 503B pharmacies under physician routing if appropriate. PSI maintains a vetted directory of practitioners with peptide experience operating within validated clinical practice frameworks including primary care, telehealth, endocrinology, weight medicine, rheumatology, and other specialties per AMA Code of Medical Ethics + FDA prescribing information.

Find a verified physician

PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.

Browse the directory Learn about the verification process →

Related Conditions

Related Education

Featured Compounds

Common Contexts

· Adult considering FDA-approved peptide therapy through primary care, telehealth, or specialty practice
· Adult exploring compounded peptide pathway through 503A or 503B pharmacy under physician routing
· Adult considering off-label use of FDA-approved peptide with AMA Code 1.1.5 documented informed consent
· Adult evaluating telehealth peptide consultation with appropriate state licensure verification
· Patient distinguishing therapeutic peptide drugs from DSHEA supplements like collagen peptides and creatine
· Patient evaluating research-grade peptide product offers against FDA framework and FDA-approved alternatives
· Patient offered peptide therapy without physician evaluation and verifying prescription pathway legitimacy
· Adult considering compounded GLP-1 receptor agonist with FDA scrutiny context awareness
· Patient comparing FDA-approved Wegovy or Ozempic against compounded semaglutide alternatives
· Patient understanding the legal distinction between research-grade peptides and prescription therapeutic peptides

Important Context

This page is educational and does not constitute medical advice. The information presented reflects federal drug law including the Federal Food Drug and Cosmetic Act, FDA prescribing information for FDA-approved peptides, the FDA Compounding Quality Act framework for 503A pharmacies and 503B outsourcing facilities, AMA Code of Medical Ethics 1.1.5 and 2.1.1, and state pharmacy board oversight standards as referenced.

Your physician will evaluate your specific clinical context, medical history, comorbidities, medications, and preferences when assessing any peptide therapy decision. The prescription pathways described here are general and do not substitute for individualized clinical judgment. Specialty coordination strengthens complex decisions.

Educational content only. Discuss with your physician before starting, stopping, or modifying any therapy. Self-sourcing therapeutic peptides operates outside validated clinical practice and carries unknown quality, sterility, and legal exposure risks. Research-grade peptide labels stating not for human use have legal meaning under FDA enforcement framework.

Sources and Citations

[1] FDA Prescribing Information: Wegovy (semaglutide) injection 2.4 mg · 2024 · FDA NDA 215256 · Source
[2] FDA Prescribing Information: Ozempic (semaglutide) injection · 2024 · FDA NDA 209637 · Source
[3] FDA Prescribing Information: Zepbound (tirzepatide) injection · 2024 · FDA NDA 217806 · Source
[4] FDA Prescribing Information: Forteo (teriparatide) injection · 2020 · FDA NDA 021318 · Source
[5] FDA Prescribing Information: Evenity (romosozumab-aqqg) injection with cardiovascular boxed warning · 2019 · FDA NDA 761062 · Source
[6] Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT trial) · New England Journal of Medicine · 2023 · DOI
[7] Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) · New England Journal of Medicine · 2022 · DOI
[8] AMA Code of Medical Ethics Opinion 1.1.5: Off-label and Investigational Use of Pharmaceuticals · American Medical Association · 2024 · Source
[9] AMA Code of Medical Ethics Opinion 2.1.1: Informed Consent · American Medical Association · 2024 · Source
[10] American Diabetes Association. Standards of Care in Diabetes 2024 · Diabetes Care · 2024 · DOI
[11] Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis - 2020 Update · Endocrine Practice · 2020 · DOI
[12] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on the Management of Blood Cholesterol · Circulation · 2018 · DOI
[13] FDA Compounding Quality Act framework: 503A pharmacy compounding under state oversight; 503B outsourcing facilities under FDA registration · US Food and Drug Administration · 2023 · Source
[14] Federal Food, Drug, and Cosmetic Act Section 503(b) - prescription drug status framework · US Food and Drug Administration · 2024 · Source

Medical Disclaimer

This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.